Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Sickle Cell DiseaseSickle Cell Anemia
Interventions
DRUG

Pociredir oral capsule(s)

Participants will receive Pociredir

Trial Locations (23)

2193

RECRUITING

Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg

10461

RECRUITING

Jacobi Medical Center, The Bronx

11432

RECRUITING

Queens Hospital Cancer Center, Jamaica

21237

WITHDRAWN

Axon Clinical Research Institute, Baltimore

22031

RECRUITING

Inova Schar Cancer Institute, Fairfax

23298

RECRUITING

Virginia Commonwealth University, Richmond

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

30315

RECRUITING

Sonar Research Center, Atlanta

30329

WITHDRAWN

Visionaries Clinical Research, Atlanta

30331

WITHDRAWN

Atlanta Center for Medical Research, Atlanta

30912

WITHDRAWN

Augusta University, Augusta

33021

WITHDRAWN

Foundation for Sickle Cell Disease Research, LLC, Hollywood

33136

WITHDRAWN

University of Miami Health System, Miami

39110

WITHDRAWN

Mississippi Center for Advanced Medicine, Madison

70808

RECRUITING

Our Lady of the Lake Hospital, Baton Rouge

72205

RECRUITING

University of Arkansas for Medical Sciences (UAMS), Little Rock

73112

RECRUITING

Lynn Health Science Institute, Oklahoma City

77030

RECRUITING

University of Texas Houston, Houston

90095

RECRUITING

University of California, Los Angeles, Los Angeles

200212

RECRUITING

University of Ibadan, Ibadan

800125

RECRUITING

Barau Dikko Teaching Hospital, Kaduna

900247

RECRUITING

National Hospital, Abuja, Abuja

02118

RECRUITING

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Fulcrum Therapeutics

INDUSTRY